Regarding: A global anti-B cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome

The Original Article is available

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Dossier C, Prim B, Moreau C, Kwon T, Maisin A, Nathanson S, De Gennes C, Barsotti K, Bourrassi A, Hogan J, Deschênes G (2020) A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. Pediatr Nephrol. https://doi.org/10.1007/s00467-020-04811-0

  2. 2.

    Said R, Tsimberidou AM (2017) Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. Expert Opin Biol Ther 17:1463–1470

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Tam C, Kuss B, Opat S, Boulos J, Marlton P (2017) Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil. Intern Med J 47(Suppl 4):5–10

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Alan Majeranowski.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Majeranowski, A., Okrój, M. Regarding: A global anti-B cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. Pediatr Nephrol (2021). https://doi.org/10.1007/s00467-021-04981-5

Download citation